US drugs and medical devices maker Abbott said that it has received the Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a new molecular point-of-care test that can detect novel coronavirus (COVID-19) in as little as five minutes.
The test named ID NOW COVID-19 is an instrument-based lightweight (6.6 pounds) and portable isothermal system for the qualitative detection of infectious diseases. Harnessing molecular technology for its high degree of accuracy, the platform delivers positive results just in five minutes and reconfirms negative results in 13 minutes.
“The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus,” said Robert B. Ford, president and chief operating officer, Abbott.
“With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots,” he added.